Pirtobrutinib in covalent BTK-inhibitor pre- treated relapsed/refractory (R/R) Mantle Cell Lymphoma

被引：0

作者：

Fileni, Caroline ^{[1
]}

Sarkozy, Clementine ^{[2
]}

机构：

[1] Hop Archet 1, Serv Hematol, Nice, France

[2] Inst Curie St Cloud, Serv Hematol, St Cloud, France

来源：

BULLETIN DU CANCER | 2023年 / 110卷 / 10期

关键词：

Mantle cell lymphoma; Relapse; Refractory; Covalent BTK-inhibitor; Non covalent BTK-inhibitor;

D O I：

10.1016/j.bulcan.2023.07.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：988 / 990

页数：3

共 50 条

[41] Safety and Efficacy of Tinostamustine in Heavily Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
Ghesquieres, Herve
Pinto, Antonio
Sureda, Anna
Tournilhac, Olivier
Morschhauser, Franck
Janik, Tomas
Zinzani, Pier Luigi
BLOOD, 2021, 138
[42] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)
Mehta, Amitkumar
Trneny, Marek
Walewski, Jan
Ribrag, Vincent
Dartigeas, Caroline
Christensen, Jacob Haaber
Pane, Fabrizio
Rodriguez, Guillermo
Taszner, Michal
Venugopal, Parameswaran
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Zinzani, Pier Luigi
BLOOD, 2020, 136
[43] PATIENT REPORTED OUTCOMES AMONG KTE-X19 CAR T TREATED PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL)
Kersten, Jose M.
Munoz, J.
Milpied, N.
Maglinte, G.
Crawford, S.
Solem, C.
Rao, A., V
Wang, M.
VALUE IN HEALTH, 2020, 23 : S479 - S479
[44] Long-term safety with ≥ 12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies
Muehlenbein, Catherine E.
Coombs, Catherine C.
Shah, Nirav
Jurczak, Wojciech
Woyach, Jennifer
Cheah, Chan Y.
Patel, Krish
Maddocks, Kami
Wang, Yucai
Wang, Chunxiao
Abhyankar, Sarang
Tsai, Donald E.
Eyre, Toby A.
LEUKEMIA & LYMPHOMA, 2023, 64 : S77 - S78
[45] COST-EFFECTIVENESS ANALYSIS FOR ACALABRUTINIB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL) IN CHINA
Chang, S.
He, X.
VALUE IN HEALTH, 2024, 27 (06) : S95 - S95
[46] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
Munoz, Javier
Reagan, Patrick M.
Goy, Andre
Miklos, David B.
Zheng, Dan
Fang, Xiang
Shen, Rhine R.
Siddiqi, Rubina
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael
ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
[47] COMPARATIVE EFFECTIVENESS OF TREATMENTS FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL), USING MATCHING ADJUSTED INDIRECT COMPARISON
Tongbram, V
Sengupta, N.
Gaudig, M.
Sidhu, M.
Exuzides, A.
Colby, C.
Sanden, S., V
McGovern, A.
VALUE IN HEALTH, 2014, 17 (07) : A614 - A615
[48] Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Izutsu, Koji
Ma, Shuo
Flinn, Ian
Alencar, Alvaro J.
Lewis, David
Patel, Krish
Maddocks, Kami
Wang, Yucai
Munir, Talha
Zelenetz, Andrew D.
Balbas, Minna
Tsai, Donald E.
Wang, Chunxiao
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S459 - S459
[49] Successful treatment with Pola-R-mini-CHP for elderly relapsed and refractory mantle cell lymphoma
Oka, Satoko
Akagi, Yuina
Ono, Kazuo
ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5981 - 5983
[50] Real-World (RW) Comparative Effectiveness of Covalent Bruton Tyrosine Kinase Inhibitors (cBTKis) Among Patients With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Phillips, Tycel
Guinter, Mark A.
Miller, Taavy A.
Wang, Jingru
Pierre, Amy
Maglinte, Gregory A.
Seymour, Erlene K.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S517 - S517

← 1 2 3 4 5 →